Cutler Group’s Roivant Sciences ROIV Stock Holding History

Cutler Group’s Portfolio ROIV Stock Details ROIV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	–	Sell	-3,300	Closed	-$6K	–	5418
2022 Q2	$6K	Hold	3,300	–	–	﹤0.01%	3613
2022 Q1	$5K	Buy	+3,300	New	+$21.8K	﹤0.01%	4166

Other funds holding ROIV

QVT Financial New York $1.37B AUM 148.1% 1-Year Est. Return

SIAU

SB Investment Advisers (UK) London, United Kingdom $7.73B AUM 2.35% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

RCMNY

Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

PSC

Patient Square Capital Menlo Park, California $564M AUM 261.3% 1-Year Est. Return

Cutler Group's ROIV Position: Q4 2023 in Review

Cutler Group sold out of Roivant Sciences (ROIV) in Q4 2023, closing a stake of 300 shares — an estimated $3K sold.

Cutler Group first reported a position in ROIV in Q1 2022 and held it in 3 quarters. The position peaked at $28K in Q1 2022. 224 funds tracked by Wall St. Rank hold ROIV as of Q4 2023.

Cutler Group reported no remaining Roivant Sciences position as of Q4 2023 after selling out during the quarter.
Cutler Group sold 300 Roivant Sciences shares in Q4 2023, an estimated $3K.
Cutler Group first reported a position in Roivant Sciences in Q1 2022 and held it in 3 quarters.
Cutler Group's Roivant Sciences position peaked at $28K in Q1 2022.
224 funds tracked by Wall St. Rank held Roivant Sciences as of Q4 2023.

Based on Cutler Group's 13F filing for Q4 2023, filed 18 Jan 2024.